Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Berek

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
European Journal of Neurology|December 28, 2020
Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC scoreGabriel Bsteh, Harald Hegen, Katharina Riedl, et al.
Frontiers in Immunology|January 3, 2024
Diagnostic value of kappa free light chain index in patients with primary progressive multiple sclerosis - a multicentre studyHarald Hegen, Klaus Berek, Paola Cavalla, et al.
Journal of Neurology|June 9, 2026
Integration of retinal layer thinning into NEDA-3 predicts disability progression in multiple sclerosisFabian Föttinger, Nik Krajnc, Klaus Berek, et al.
European Journal of Neurology|December 17, 2024
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcomeGabriel Bsteh, Robert Hoepner, Jonathan A Gernert, et al.
Journal of Neurology|October 19, 2023
Multiple sclerosis in the elderly: a retrospective cohort studyAnne Zinganell, Georg Göbel, Klaus Berek, et al.
Frontiers in Immunology|November 24, 2025
Prognostic value of kappa free light chain index in patients with primary progressive multiple sclerosisMartin Schmidauer, Klaus Berek, Michael Auer, et al.
Neurology|August 28, 2024
Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI ActivityGabriel Bsteh, Marie L Aicher, Janette F Walde, et al.
European Journal of Neurology|January 30, 2026
Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple SclerosisNicolás Fissolo, Pascal Benkert, Andreu Vilaseca-Jolonch, et al.
Journal of Neurology|September 28, 2018
Multifocal motor neuropathy in Austria: a nationwide survey of clinical features and response to treatmentWolfgang N Löscher, Eva-Maria Oberreiter, Marcus Erdler, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 24, 2024
Association of Complement Factors With Disability Progression in Primary Progressive Multiple SclerosisJan D Lunemann, Harald Hegen, Luisa María Villar, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
European Journal of Neurology|December 28, 2020
Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC scoreGabriel Bsteh, Harald Hegen, Katharina Riedl, et al.
Frontiers in Immunology|January 3, 2024
Diagnostic value of kappa free light chain index in patients with primary progressive multiple sclerosis - a multicentre studyHarald Hegen, Klaus Berek, Paola Cavalla, et al.
Journal of Neurology|June 9, 2026
Integration of retinal layer thinning into NEDA-3 predicts disability progression in multiple sclerosisFabian Föttinger, Nik Krajnc, Klaus Berek, et al.
European Journal of Neurology|December 17, 2024
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcomeGabriel Bsteh, Robert Hoepner, Jonathan A Gernert, et al.
Journal of Neurology|October 19, 2023
Multiple sclerosis in the elderly: a retrospective cohort studyAnne Zinganell, Georg Göbel, Klaus Berek, et al.
Frontiers in Immunology|November 24, 2025
Prognostic value of kappa free light chain index in patients with primary progressive multiple sclerosisMartin Schmidauer, Klaus Berek, Michael Auer, et al.
Neurology|August 28, 2024
Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI ActivityGabriel Bsteh, Marie L Aicher, Janette F Walde, et al.
European Journal of Neurology|January 30, 2026
Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple SclerosisNicolás Fissolo, Pascal Benkert, Andreu Vilaseca-Jolonch, et al.
Journal of Neurology|September 28, 2018
Multifocal motor neuropathy in Austria: a nationwide survey of clinical features and response to treatmentWolfgang N Löscher, Eva-Maria Oberreiter, Marcus Erdler, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 24, 2024
Association of Complement Factors With Disability Progression in Primary Progressive Multiple SclerosisJan D Lunemann, Harald Hegen, Luisa María Villar, et al.
Pageof 10